Forest buys Merck drug, reveals reorganization plan
This article was originally published in Scrip
Executive Summary
New Forest Laboratories president and CEO Brent Saunders apparently jumped into his leadership roles ready to broker deals and make changes, since the company announced its acquisition of a Merck schizophrenia drug and detailed a plan to "streamline" Forest's operations a month ahead of schedule.